Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Second-line Treatment
100%
Tyrosine Kinase Inhibitor
50%
Immune Checkpoint Inhibitors
50%
Toxicity Profile
25%
Literature Search
25%
PubMed
25%
Disease Progression
25%
Functional Status
25%
Treatment Strategy
25%
First-line Therapy
25%
Treatment Options
25%
Improved Outcomes
25%
Manual Search
25%
Safety Profile
25%
Unmet
25%
Practical Guide
25%
Patient's Will
25%
Risk Score
25%
Embase
25%
Everolimus
25%
Further Treatment
25%
Rechallenge
25%
Combination Regimen
25%
Patient Preference
25%
Head-to-head Trials
25%
Treatment Decisions
25%
Treatment Selection
25%
Efficacy-toxicity
25%
Systemic Treatment
25%
Second-line Therapy
25%
Immediate Response
25%
Conference Proceedings
25%
Immunosuppressive Drugs
25%
Individualized Care
25%
Narrative Review
25%
Metastatic RCC
25%
Hypoxia-inducible factor-2α (HIF-2α)
25%
Sarcomatoid
25%
Biomarkers Treatment
25%
Early Progression
25%
Treatment Landscape
25%
Medicine and Dentistry
Kidney Metastasis
100%
Clinician
50%
Tyrosine-Kinase Inhibitor
50%
Immune Checkpoint Inhibitor
50%
Biological Marker
25%
Disease Exacerbation
25%
Functional Status
25%
Systemic Therapy
25%
Everolimus
25%
Patient Preference
25%
Immunosuppressive Drug
25%
Sarcomatoid
25%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
100%
Protein Tyrosine Kinase Inhibitor
50%
Immune Checkpoint Inhibitor
50%
Immunosuppressive Agent
25%
Biological Marker
25%
Disease Exacerbation
25%
Everolimus
25%
Functional Status
25%
Systemic Treatment
25%